

## Detecting Common CFTR Mutations by Reverse Dot Blot Hybridization Method in Cystic Fibrosis First Report from Northern Iran

Mohammad-Reza Esmaeili Dooki<sup>1</sup>, MD; Haleh Akhavan-Niaki<sup>\*2</sup>, PhD, and Ali Ghabeli Juibary<sup>2</sup>, MD

1. Non-Communicable Pediatric Diseases Research Center, Babol University of Medical Sciences, Babol, Iran
2. Cellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, Iran

Received: Jun 01, 2010; Final Revision: Oct 29, 2010; Accepted: Nov 13, 2010

### Abstract

**Objective:** Cystic fibrosis and its distribution vary widely in different countries and/or ethnic groups. Common cystic fibrosis transmembrane conductance regulator (CFTR) mutations were reported from Iran, but the northern population was not or underrepresented in those studies. The aim of this study was to determine the frequency of common CFTR mutations in children from northern Iran.

**Methods:** Thirty unrelated Iranian cystic fibrosis patients aged less than 11 years and living in Mazandaran province (in Iran) were screened for 5 common CFTR gene mutations. deltaF508, N1303K, G542X, R347H and W1282X using Reverse Dot Blot method.

**Findings:** Only one mutation, DeltaF508, was found in 7 patients accounting for 21.7% (13/60) of alleles.

**Conclusion:** These findings can be used for planning future screening and appropriate genetic counseling programs in Iranian CF families.

*Iranian Journal of Pediatrics, Volume 21 (Number 1), March 2011, Pages: 51-57*

**Key Words:** Cystic Fibrosis; CFTR; Genotype; DeltaF508-CFTR; Children; Iran

### Introduction

Cystic fibrosis (CF) is an autosomal recessive disease caused by defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The protein product of the gene is a chloride channel and a member of the ATP-binding cassette membrane transporter superfamily. The CFTR

channel is critical for the normal function of epithelial cells in the lungs, pancreas, intestine, gall bladder, and sweat glands. Excess mucus in the respiratory system of CF patients facilitates chronic bacterial infections, leading to respiratory failure, which is the major cause of mortality. Most of the patients also fail to produce digestive enzymes in the pancreas, resulting in pancreatic

\* Corresponding Author;

Address: Cellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, Iran

E-mail: halehakhavan@yahoo.com

© 2011 by Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, All rights reserved.

insufficiency. Other clinical features are variably associated with the disease<sup>[1]</sup>.

Approximately one in 2000 to 3000 newborns in populations of European ancestry are affected, and the average carrier frequency is about 1:25<sup>[2,3]</sup>. The p.F508del ( $\Delta$ F508) allele of the gene is the most common mutation observed worldwide and is probably very old, dating to pre-Neolithic times<sup>[2,4]</sup>. In addition to the  $\Delta$ F508 mutation, more than 1000 other mutations in the CFTR gene have been identified (CF Genetic Analysis Consortium <http://www.genet.sickkids.on.ca/cftr>). These mutations vary greatly in their frequency and distribution, but most are very rare. Only four (p.G542X, p.N1303K, p.G551D and p.W1282X) have overall frequencies higher than 1%<sup>[5]</sup>.

Intriguingly, p.G542X and p.N1303K are found on the same haplotype background as  $\Delta$ F508, suggesting that they arose in the same population<sup>[6]</sup>.

Few previous reports of CFTR mutations in Iran have been published<sup>[7-9]</sup>. In the present study, 5 of the 27 CFTR exons of 30 unrelated northern Iranian CF patients were analyzed with the aim of detecting common CFTR mutations in this population. In addition, the clinical presentations and laboratory findings were studied based on hospital and outpatient records.

We selected five mutations, deltaF508, N1303K, G542X, R347H and W1282X based on previous reports in Iran and neighboring countries. The knowledge of the mutation spectrum and its frequency in this population will improve the diagnosis and medical care of CF patients and could also be used as a basis for carrier screening and prenatal diagnosis programming in Iran.

Several techniques such as allele specific oligonucleotide (ASO) dot-blot, reverse dot-blot, amplification refractory mutation (ARMS), and an oligo-ligation assay, are available to detect the most common mutations<sup>[10]</sup>. The reverse dot-blot (RDB) technique is one of the most widely used techniques to diagnose CF<sup>[11-14]</sup>. This technique was evaluated as routine first-line analyses of the CFTR gene status<sup>[12,15]</sup>. RDB is more advantageous than other techniques since it does not necessitate the use of radiolabeled probes as in Allele Specific Oligonucleotide assay and the use of positive controls to show the proper functioning of PCR

reaction in each tube as in ARMS assays, since in ARMS technique, results are based on the absence of PCR products<sup>[13]</sup>. In this study all 5 mutations were screened simultaneously using reverse dot blot (RDB) assay.

## Subjects and Methods

### Patients:

The 30 patients were diagnosed as cystic fibrosis based on elevated sweat chloride values (>60 mEq/L) and were 6 weeks to 11 years old. Many patients had pulmonary complications and pancreatic insufficiency. The patients were recruited from a pediatric hospital (Amirkola Children's Hospital) in Mazandaran province, northern Iran. Some of them were diagnosed by the pediatric gastroenterologist in office. The patients originated from many different regions of Mazandaran. Families of the patients were informed of the nature of the research and consented to participate in this study.

### Molecular Analysis:

DNA from the leukocytes of peripheral blood was prepared by the salting out protocol. Mutation detection was performed using Reverse Dot Blot (RDB) procedure, as described by Lappin et al<sup>[16]</sup>. In this assay, oligonucleotide probes were synthesized using a C6-amino-linker on the 5' end of the product and were attached onto Biotinylated nylon membrane (Pall Corporation) activated by 1-Ethyl 3-Dimethyl Aminopropyl Carbodiimide (EDAC). The target DNA was amplified with 5' biotinylated primers and hybridized to immobilized oligonucleotides on the membrane. Hybridization was detected by adding streptavidin-horseradish peroxidase to the membrane where it bound to biotinylated DNA that was hybridized to the oligonucleotides. A positive signal could then be obtained by a simple non-radioactive colorimetric reaction.

CFTR amplifications took place in 50- $\mu$ L reactions containing 1X PCR buffer (10 mmol/L KCl, 10 mmol/L Tris-HCl, pH 8.3, 1.5 mmol/L MgCl<sub>2</sub>) and 6 mmol/L MgCl<sub>2</sub>, 200  $\mu$ mol/L each of dNTPs, 10 pmol of each primer, and 1.5 units of

## Archive of SID

Taq DNA polymerase. All PCR reagents (except primers which were from MWG, Germany) were from Roche Company.

PCR was performed in a Techgene thermocycler from Techne Co., (UK). Thermo-cycling conditions were uniform for all reactions and included an initial denaturation step at 95°C for 3 minutes, followed by 38 cycles of denaturation at 95°C for 30 seconds, annealing at 54°C for 30 seconds and polymerization at 72°C for 30 seconds. Cycling culminated with a final extension at 72°C for 4 minutes. PCR products were visualized after electrophoresis on 1.5% Agarose LE gel under 302nm UV lamp.

The hybridization reaction took place after adding the pooled PCR products to Biodyne membranes pre-wet with hybridization buffer [2X saline sodium citrate (SSC), 0.1% sodium dodecyl sulfate (SDS)] at 42°C. The amplicons and membranes were boiled and permitted to hybridize for 1 hour at 42°C. Hybridization solutions were poured off and membranes were washed twice in excess of wash buffer (0.75\_ SSC, 0.1% SDS). Membranes were then agitated in a freshly prepared conjugate solution (1:4000 dilution of streptavidin-horseradish peroxidase conjugate, (Boehringer Mannheim, Part No. 1089153), in 0.5X SSC, 0.1% SDS for 30 minutes at room temperature. At the end of the incubation, membranes were washed three times for 3 minutes each with 0.5X SSC, 0.1% SDS; then twice for three minutes each with 0.1 mol/L sodium citrate, pH 5.0. The membranes were then exposed to 0.01% w/v tetramethylbenzidine dihydro-

chloride (TMB) substrate (Sigma T-8768) in a freshly prepared, dilute solution of hydrogen peroxide (0.00225% v/v) in 0.1M sodium citrate, pH 5.0 with agitation for 10 to 20 minutes. Color development was stopped by rinsing the membranes with distilled water. The details of probes and primers (MWG Biotech, Germany) used in this study are presented in Tables 1 and 2 respectively and were described previously by Lappin et al<sup>[16]</sup>.

## Findings

### Phenotype Analysis:

30 unrelated patients (17 males and 13 females) aged 6 weeks to 11 years originating from Mazandaran province, Iran were analyzed in this study. Half of the patients were issued from consanguineous marriage (mostly between first cousins). All patients showed acute or persistent respiratory symptoms. 26 patients had failure to thrive and malnutrition and 25 patients had abnormal stools. None of the patients had a previous family history of CF. Other manifestations such as meconium ileus, intestinal obstruction, electrolyte abnormality, rectal prolapse, nasal polyps, sinus disease, diabetes mellitus, liver or gallbladder problems were observed in a small number of patients.

The phenotype of subjects carrying CFTR mutations is reported in Table 3.

**Table 1:** Human cystic fibrosis transconductance regulator probes

Probe name	Location in the CFTR gene	CFTR probe sequence
<b>ΔF508-N</b>	Exon10	5'-NH2-GAAACACCAAAGATGATA-3'
<b>ΔF508-MUT</b>	Exon10	5'-NH2-GGAAACACCAATGATATT-3'
<b>G542X-N</b>	Exon11	5'-NH2-TATAGTTCTTGGAGAAGGTG3'
<b>G542X-MUT</b>	Exon11	5'-NH2-TATAGTTCTTTGAGAAGGTG-3'
<b>W1282X-N</b>	Exon20	5'-NH2-GCTTTCCTCCACTGTTG-3'
<b>W1282X-MUT</b>	Exon20	5'-NH2-CAACAGTGAAGGAAAGC-3'
<b>N1303K-N</b>	Exon21	5'-NH2-AGAAAAAACTTGATCC-3'
<b>N1303K-MUT</b>	Exon21	5'-NH2-GGGATCCAACCTTTTTTCT-3'
<b>R347H-N</b>	Exon7	5'-NH2-AATTGTTCTGCGCATGG-3'
<b>R347H-MUT</b>	Exon7	5'-NH2-CATTGTTCTGCCCATGGC-3'

**Table 2:** Human cystic fibrosis transmembrane conductance regulator primers

Cystic fibrosis mutation tested	Cystic fibrosis primer name	Exon amplified	Cystic fibrosis primer sequence
<b>R347P</b>	CF7-F	7	5'-Biotin-AGACCATGCTCAGATCTTCCAT-3'
	CF7-R		5'-Biotin-GCAAAGTTCATTAGAACTGATC-3'
<b>ΔF508</b>	CF10-F	10	5'-Biotin-GCAGAGTACCTGAAACAGGA-3'
	CF10-R		5'-Biotin-CATTCACAGTAGCTTACCCA-3'
<b>G542X</b>	CF11-F	11	5'-Biotin-CAACTGTGGTTAAAGCAATAGTGT-3'
	CF11-R		5'-Biotin-GCACAGATTCTGAGTAACCATAAT-3'
<b>W1282X</b>	CF20-F	20	5'-Biotin-TGGGCCTCTTGGGAAGAAGT-3'
	CF20-R		5'-Biotin-CTCACCTGTGGTATCACTCC-3'
<b>N1303K</b>	CF21-F	21	5'-Biotin-GGTAAGTACATGGGTGTTTC-3'
	CF21-R		5'-Biotin-CAAAGTACCCTGTTGCTCCA-3'

**Genotype Analysis:**

Mutation screening of the CFTR gene in 60 alleles by reverse dot blot hybridization for five common mutations showed that 13 (21.6%) alleles were ΔF508. Six patients were homozygous for ΔF508 and one patient was compound heterozygous for whom only one allele was specified. The other four mutations tested (N1303K, G542X, R 347H and W1282X) were not encountered in these patients.

**Genotype-Phenotype Correlation:**

Table 4 shows phenotypes of 7 patients carrying deltaF508 mutation. All had respiratory difficulties and failure to thrive. Six of them evacuated abnormal stools and 4 had meconium ileus. Other manifestations such as edema and hypoproteinemia, liver and gallbladder problems,

rectal prolapse, or diabetes mellitus were encountered in a lower incidence (one or two patients).

**Discussion**

Few molecular studies are performed in Iranian CF patients<sup>[7-9]</sup>. As Mazandaran CF patients were underrepresented (2 out of 69 patients)<sup>[9]</sup> or not included in those studies, and regarding the high genetic heterogeneity observed among different provinces of Iran in other disease causing genes<sup>[17-19]</sup> and also considerable heterogeneity in the nature of CFTR mutations observed among Iranian

**Table 3:** phenotype of subjects carrying CFTR mutations

Clinical presentations	Number of patients
Acute or persistent respiratory symptoms	30
Failure to thrive, malnutrition	26
Abnormal stools	25
Meconium ileus, intestinal obstruction	7
Family history	0
Electrolyte, acid-base abnormality	2
Rectal prolapse	2
Nasal polyps, sinus disease	3
Liver, gallbladder problems	4
Other*	4

\*Other: acrodermatitis like rash, vitamin deficiency states, hypoproteinemic edema, hypoprothrombinemia with bleeding, meconium plug syndrome, diabetes mellitus

**Table 4:** Phenotypes of 7 patients carrying delta F508 mutation

Clinical presentations	Number of patients
Acute or persistent respiratory symptoms	7
Failure to thrive, malnutrition	7
Abnormal stools	6
Meconium ileus, intestinal obstruction	4
Edema and hypoproteinemia	2
Liver, gallbladder problems	2
Rectal prolapse	1
Diabetes mellitus	1

cystic fibrosis patients<sup>[7-9]</sup>, the molecular characterization of CF in Mazandaran province seems a necessity. Using Reverse Dot Blot method, 5 common CFTR mutations were analyzed in this study in 30 CF patients (13 males and 17 females) aged 6 weeks to 11 years, originating from Mazandaran province and presenting acute or persistent respiratory symptoms and failure to thrive. This method is a simple, rapid and reliable method which allows simultaneous detection of up to 20 different mutations in a single hybridization assay<sup>[13]</sup>.

Delta F508 mutation was present in 13 (21.6%) alleles tested by RDB assay. Six patients were homozygous and one was compound heterozygote for this mutation. The other four mutations tested: N1303K, G542X, R347H and W1282X, were not found in these patients. These mutations were previously reported in most parts of the world<sup>[21,22]</sup> including neighboring countries<sup>[23-28]</sup> and also other provinces of Iran<sup>[7-9]</sup>.

Only one disease-causing mutation was identified in this study.

Although the frequency of the  $\Delta$ F508 among Mazandarani patients was lower (21.6%) than its frequency in European countries, it was still the most frequent mutation among those reported to date in Iran. Previous studies representing overall Iranian CF patients reported a frequency of 16-17.8% for this mutation.

This difference could be due to the small number of Mazandarani patients in this study and suggests heterogeneity of Iranian provinces regarding CF mutations. Moreover, its frequency is comparable with those reported in several countries in west Asia, north Africa and Indian subcontinent (Algeria 16.7%, Tunisia 18%, Turkey

24-27%, Saudi Arabia 13%, Pakistan 17%, India 19-27%<sup>[6,20,21, 24,26-30]</sup>).

Previous studies showed that the mutation spectrum in Iran had a significant overlap with that observed in Turkey and was less similar to its spectrum observed in Europe. Specifically, the four most common Turkish mutations were found in Iran, including  $\Delta$ F508, c.1677delTA, p.G542X, and c.2183AA>G. The "Mediterranean mutation", p.G542X, is reported to be of Phoenician origin<sup>[7-9,29,31]</sup>. Table 5 shows the comparison of the frequency of all five mutations considered in this study in Iran and some neighboring countries.

Regarding the sample size in this study, underestimation of the other four mutations analyzed may be possible due to their low frequency.

All patients presented acute or persistent respiratory symptoms and more than 80% had failure to thrive, malnutrition and abnormal stools. Only 23.3% of patients (7 cases) had meconium ileus and intestinal obstruction among which 4 had homozygote  $\Delta$ F508 genotype. The high prevalence of meconium ileus among  $\Delta$ F508 patients was also reported in other studies<sup>[32-33]</sup>. Liver disorders which are present in 2-3% of children and 5% of adults occur in 25% of CF patients<sup>[34]</sup>. In this study 4 children presented liver disorders (13.3%) among which 2 had  $\Delta$ F508 homozygote genotype.

Frequency of carriers of a disease-causing CFTR mutation in Iranians (1:40)<sup>[8]</sup> is very similar to that in European populations (1:25). Consequently, it is believed that the incidence of cystic fibrosis is also similarly high, and that the low incidence commonly believed to be associated cystic fibrosis is also similarly high, and that the

**Table 5:** Comparison of the frequency of common CFTR mutations  $\Delta F508$ , N1303K, G542X, R347H, W1282X in Europe and North Africa with Iran and some neighboring countries

Region or Country	Mutation Type					Reference
	$\Delta F508$	W1282X	N1303K	G542X	R347H	
Europe and N Africa	66.8	1	1.6	2.6	0.8-3.6	6
Turkey	24.5-27	ND	2.9-3.7	2.6-4.9	3-3.6	6, 23, 25
Saudi Arabia	13	ND	2	ND	ND	27, 28
India	19-27	ND	ND	ND	ND	24, 26
Iran	16-17.8	0-4	4.3-5.5	1.6-3.6	1.6-3.6	7, 8, 9
Mazandaran	21.6	0	0	0	0	Present study

ND: Not detected

low incidence commonly believed to be associated with this non-European population is likely to be due to under-diagnosis. Moreover, intermediate sweat chloride levels may exist in some CF patients<sup>[35]</sup>, leading to misdiagnosis of these patients if the selection criteria is based on sweat chloride positive test as is the case in this study.

Furthermore, the frequency of CF may be higher in some isolated populations due to consanguinity, as has been previously reported in an isolated population<sup>[36]</sup>. The same assessment has been proposed for populations of Turkey and Saudi Arabia<sup>[27-29]</sup>. Therefore, in addition to Europe and the United States, CF is likely to be prevalent in many other countries as well, although the mutation spectrums may be different. Thus ascertainment of CFTR mutation carrier frequencies and CF incidence among Iranians seems to be a necessity.

## Conclusion

Our mutation detection efficiency was rather low (21.6%). However, we cannot assure how much clinical misdiagnosis contributed to this.  $\Delta F508$  was the only mutation detected and showed a frequency comparable to that reported in overall Iranian population and neighboring countries. Identification of the remaining mutations and their frequency requires to design appropriate tests to improve the clinical diagnosis and establishing CF prevention programs by carrier screening and prenatal diagnosis.

## Acknowledgment

We thank Mr. Ali Banihashemi, Mrs. Mandana Azizi and Mrs. Beheshteh Asghari for their technical assistance. This study was authorized by the Ethic Committee of Babol University of Medical Sciences.

**Conflict of Interest:** None

## References

1. Rowntree RK, Harris A. The phenotype consequences of CFTR mutations. *Ann Hum Genet* 2003;67(Pt 5):471-85.
2. Welsh MJ, Ramsey BW, Accurso F, Cutting G. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, (eds). *The Metabolic and Molecular Basis of Inherited Diseases*. 8th ed. New York: McGraw-Hill. 2001; Pp: 5121-88.
3. Farrell P. Improving the health of patients with cystic fibrosis through newborn screening. *Adv Pediatr* 2000;49:79-115.
4. Dawson K, Frossard P. The geographic distribution of cystic fibrosis mutations gives clues about population origins. *Eur J Pediatr* 2000; 159(7):496-499.
5. Estivill X, Bancells C, Ramos C. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. *Hum Mutat* 1997;10(2):135-54.
6. Mateu E. Can a place of origin of the main cystic fibrosis mutations be identified? *Am J Hum Genet* 2002;70(1):257-64.
7. Jalalirad M, Houshmand M, Mirfakhraie R, et al. First study of CF mutations in the CFTR gene of Iranian patients: detection of DeltaF508, G542X,

## Archive of SID

- W1282X, A120T, R117H, and R347H mutations. *J Trop Pediatr* 2004;50(6):359-361.
8. Elahi E, Khodadad A, Kupersmidt I, et al. A haplotype framework for cystic fibrosis mutations in Iran. *J Mol Diagnostics* 2006;8(1):119-27.
  9. Alibakhshi R, Kianishirazi R, Cassiman JJ, et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients. Identification of eight novel mutations. *J Cyst Fibros* 2008;7(2):102-9.
  10. Eshaque B, Dixon B. Technology platforms for molecular diagnosis of cystic fibrosis. *Biotechnol Adv* 2006;24(1):86-93.
  11. Picci L, Cameran M, Marangon O, et al. A 10-year large-scale cystic fibrosis carrier screening in the Italian population. *J Cyst Fibros* 2010;9(1):29-35.
  12. Huber K, Mirkovic B, Nersesian R, et al. Survey of CF mutations in the clinical laboratory. *BMC Clin Pathol* 2002;2(1):4-11.
  13. Dequeker E, Stuhrmann M, Morris MA, et al. Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders - updated European recommendations. *Eur J Hum Genet* 2009;17(1):51-65.
  14. Stuppia L, Antonucci I, Binni F, et al. Screening of mutations in the CFTR gene in 1195 couples entering assisted reproduction technique programs. *Eur J Hum Genet* 2005;13(8):959-64.
  15. Tomaiuolo R, Spina M, Castaldo G. Molecular Diagnosis of Cystic Fibrosis. Comparison of four analytical procedures. *Clin Chem Lab Med* 2003;41(1):26-32.
  16. Lappin S, Cahlik J, Gold B. Robot printing of reverse dot blot arrays for human mutation detection. *J Mol.Diagn* 2001;3(4):178-88.
  17. Bonyadi M, Omrani O, Moghanjoghi SM, et al. Mutations of the phenylalanine hydroxylase gene in Iranian Azeri Turkish patients with phenylketonuria. *Genet Test Mol Biomarkers* 2010;14(2):233-5.
  18. Abolghasemi H, Amid A, Zeinali S, et al. Thalassemia in Iran. Epidemiology, prevention, and management. *J Pediatr Hematol Oncol* 2007;29(4):233-8.
  19. Derakhshandeh-Peykar P, Akhavan-Niaki H, Tamaddoni A, et al. Distribution of beta-thalassemia mutations in the northern provinces of Iran. *Hemoglobin* 2007;31(3):351-6.
  20. Loumi O, Ferec C, Mercier B, et al. CFTR mutations in the Algerian population. *J Cyst Fibros* 2008;7(1):54-9.
  21. Bobadilla JL, Macek M Jr, Fine JP, Farrel PM. Cystic fibrosis, a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. *Hum Mutat* 2002;19(6):575-606.
  22. Lao O, Andrés AM, Mateu E, et al. Spatial patterns of cystic fibrosis mutation spectra in European populations. *Eur J Hum Genet* 2003;11(5):385-94.
  23. Yilmaz E, Erdem H, Ozgüç M, et al. Study of 12 mutations in Turkish cystic fibrosis patients. *Hum Hered* 1995;45(3):175-7.
  24. Sharma N, Singh M, Kaur G, et al. Identification and characterization of CFTR gene mutations in Indian CF patients. *Ann Hum Genet* 2009;73(1):26-33.
  25. Hundrieser J, Bremer S, Peinemann F, et al. Frequency of the F508 deletion in the CFTR gene in Turkish cystic fibrosis patients. *Hum Genet* 1990;85(4):409-10.
  26. Kabra SK, Kabra M, Lodha R, et al. Clinical profile and frequency of delta f508 mutation in Indian children with cystic fibrosis. *Indian Pediatr* 2003;40(7):612-9.
  27. Banjar H, Kambouris M, Meyer BF, et al. Geographic distribution of cystic fibrosis transmembrane regulator gene mutations in Saudi Arabia. *Ann Trop Paediatr* 1999;19(1):69-73.
  28. Banjar H. Geographic distribution of cystic fibrosis transmembrane regulator gene mutations in Saudi Arabia. *East Mediter Health J* 1999;5(6):1230-5.
  29. Kiliç M, Ninis V, Dagli E, et al. Highest heterogeneity for cystic fibrosis. 36 mutations account for 75% of all CF chromosomes in Turkish patients. *Am J Hum Genet* 2002;113(3):250-7.
  30. Shah U, Frossard P, Moatter T. Cystic fibrosis. defining a disease under-diagnosed in Pakistan. *Trop Med Int Health* 2009;14(5):542-5.
  31. Loirat F, Hazout S, Lucotte G. G542X as a probable Phoenician cystic fibrosis mutation. *Hum Biol* 1997;69(3):419-25.
  32. Navarro H, Kolbach M, Repetto G, et al. Correlation between phenotype and genotype in a group of patients with cystic fibrosis. *Rev Med Chil* 2002;130(5):475-81.
  33. Feingold J, Guilloud-Bataille M. Genetic comparisons of patients with cystic fibrosis with or without meconium ileus. Clinical Centers of the French CF Registry. *Ann Genet* 1999;42(3):147-50.
  34. Akata D, Akhan O. Liver manifestations of cystic fibrosis. *Eur J Radiol* 2007;61(1):11-7.
  35. Penmatsa H, Frederick CA, Nekkhalapu S, et al. Clinical and molecular characterization of S1118F-CFTR. *Pediatr Pulmonol* 2009;44(10):1003-9.
  36. Chiba-Falek O, Nissim-Rafinia M, Argaman Z, et al. Screening of CFTR mutations in an isolated population. Identification of carriers and patients. *Eur J Hum Genet* 1998;6(2):181-4.